University of California San Francisco

California, United States

University of California San Francisco

California, United States
SEARCH FILTERS
Time filter
Source Type

News Article | May 28, 2017
Site: www.prweb.com

Florida Pain Relief Group, a division of Physician Partners of America (PPOA), is proud to announce that Sheldon K. Cho, MD, has joined its Winter Haven practice. Dr. Cho’s practice focuses on comprehensive interventional pain management, a specialty that concentrates on minimally invasive techniques to treat and manage many types of pain. Dr. Cho is a board-certified anesthesiologist with subspecialty qualifications in interventional pain medicine. His other key areas of interest include cancer pain management, and various procedures under fluoroscopy including spinal cord stimulator trail and implant, spine kyphoplasty, RFA, facet joint block, and epidural block. He holds certifications from the American Board of Pain Management, the American Board of Anesthesiology and the American Board of Addiction Medicine. He is also a member of the American Society of Interventional Pain Physicians, and the ASA with a subspecialty in pain management. He earned his Bachelor of Science degree from Seoul National University, South Korea, and his medical degree from Seoul National University College of Medicine. He completed his surgery internship and anesthesiology residency at Nassau University Medical Center, Long Island, NY. Cho then completed a Cancer Pain Medicine fellowship in New York, NY with Memorial Sloan-Kettering Cancer Center’s Anesthesiology Department. He continued his medical career as a clinical instructor at the University of Rochester Medical Center, specializing in anesthesia regional block and pain medicine. He later served as clinical assistant professor at the University of California San Francisco UCSF and then as medical director at Anapa Pain Clinic in Los Angeles, specializing in interventional pain management. Dr. Cho sees his career as an opportunity to change a patient’s quality of life with proper pain management and interventional techniques. His patients, even those facing complex chronic pain issues, are put at ease with his reassurance and communication skills. For an appointment with Dr. Cho at Florida Pain Relief Group - Winter Haven, 7518 Cypress Gardens Blvd., call (321) 735-6218. The clinic is open from 9 a.m. to 5 p.m. Monday through Friday. Same-day appointments are often available. Physician Partners of America (PPOA) is a national healthcare organization focused on strengthening the doctor-patient relationship and improving patient outcomes. Founded in 2013 and headquartered in Tampa, Fla., PPOA and its affiliates – Florida Pain Relief Group, Texas Pain Relief Group, Texas Foot and Ankle Group, Urgent Care of Texas and National Medical Practices – share a common vision of ensuring the wellbeing of patients and providing their physician partners the opportunity to focus on the practice of medicine. This model allows physicians to be physicians, caring about patients and their needs in the face of ever more complex administrative requirements. For more information about Physician Partners of America, visit http://www.physicianpartnersofamerica.com.


News Article | May 25, 2017
Site: www.rdmag.com

Tregs, a type of immune cell, may be the key in promoting healthy hair growth in humans. Researchers from the University of California San Francisco have discovered that when Tregs, which are associated with controlling inflammation and directly trigger stem cells in the skin are absent, the stem cells are unable to regenerate hair follicles, leading to baldness. “Our hair follicles are constantly recycling: when a hair falls out, the whole hair follicle has to grow back,” Dr. Michael Rosenblum, Ph.D., an assistant professor of dermatology at UCSF and senior author on the new paper, said in a statement. “This has been thought to be an entirely stem cell-dependent process but it turns out Tregs are essential. “If you knock out this one immune cell type, hair just doesn't grow.” According to the researchers, defects in Tregs might be responsible for alopecia areata—an autoimmune disorder that causes hair loss and could play a role in other forms of baldness including male pattern baldness. The researchers developed a technique for temporarily removing Tregs from the skin and tested it on mice. However, when they shaved patches of hair from the mice to make observations of the affected skin they found that the hair never grew back. After conducting imaging experiments, the researchers discovered that Tregs has a close relationship with the stem cells that reside within hair follicles and allow them to regenerate. By removing the T cells from the skin, hair growth was blocked only if it was done within the first three days after shaving a patch of skin, when follicle regeneration would normally be activated. However, if Tregs is removed once the regeneration had already started there was no impact on hair regrowth. Tregs inform the rest of the immune system of the difference between harmful entities in the body and helpful ones. When the cells do not properly function, a person may develop allergies to harmless substances including peanut protein or cat dander or possibly suffer from autoimmune disorders where the immune system turns on the body’s own tissues. Tregs is native to the body’s lymph nodes but can live permanently in other tissues where they seem to have evolved to assist with local metabolic functions as well as playing their normal roles as an anti-inflammatory. The researchers discovered that Tregs trigger stem cell activation directly through a cell-to-cell communication system and found that Tregs in the skin express unusually high levels of communication with a signaling protein called Jagged 1, compared to Tregs elsewhere in the body. They also found that by removing Tregs with microscopic beads covered in the protein they were able to restore communicating signaling in the stem cells and successfully active follicle regeneration. “It's as if the skin stem cells and Tregs have co-evolved, so that the Tregs not only guard the stem cells against inflammation but also take part in their regenerative work,” Rosenblum said. "Now the stem cells rely on the Tregs completely to know when it's time to start regenerating." The researchers also theorized that Tregs could play a role in wound repair because the same stem cells are responsible for helping heal the skin after an injury.


Multicenter study shows AF ablation is safe and just as effective in patients with CHD compared to those with normal hearts PHILADELPHIA--Congenital heart disease (CHD) includes a range of defects that occur in the heart which patients are born with, such as a hole in the heart's wall, a leaky valve or even an inversion in the heart's orientation. CHD was once a severe condition often resulting in early death, but now, more and more CHD patients are living long and healthy lives. Therefore, as this population grows, so does the number of patients who are treated for other complications of their disease, such as early onset atrial fibrillation (AF), a quivering or irregular heartbeat that can lead to blood clots, stroke, heart failure and other complications. AF is often treated with a catheter ablation, a minimally invasive procedure in which the areas of the heart causing the irregularity are cauterized, but until now, there was limited data to support the safety and efficacy of treating CHD patients with an AF ablation. In a new study presented today at the Heart Rhythm Society's 38th Annual Scientific Session in Chicago, researchers from the Perelman School of Medicine at the University of Pennsylvania have found that CHD patients--even with complex defects--can safely undergo ablation for AF, with similar success rates as patients with normal hearts. "Treatment for atrial fibrillation is critical, whether the patient has a normal heart or whether they have complex congenital heart disease," said the study's presenter Jackson J. Liang, DO, a third-year cardiovascular disease fellow in the Perelman School of Medicine at the University of Pennsylvania. "In fact, atrial fibrillation can be especially detrimental in patients with complex congenital heart disease since they may be more reliant on the "atrial kick" provided during sinus rhythm. Unfortunately for some CHD patients, AF ablation may be more challenging due to the presence of complex anatomy, and the optimal ablation strategy for these patients remains to be defined." In this multicenter study, researchers performed a retrospective analysis of 69 CHD patients who underwent AF ablation, by collecting data from Penn, University of Colorado, University of California San Francisco, and Texas Cardiac Arrhythmia Institute at St. David's Medical Center. Researchers looked at those who underwent AF ablation for paroxysmal (intermittent) or persistent AF between 2008 and 2016. They identified the type of CHD, and tracked the ablation strategy - pulmonary vein isolation (PVI), PVI with additional ablation, or non-PV ablation only. "Some physicians may not be aware that catheter ablation can be performed to treat atrial fibrillation in patients with congenital heart disease, and instead they may prescribe anti-arrhythmic medications," said David Frankel, MD, an assistant professor of Cardiovascular Medicine at Penn. "We hope this study will increase awareness of catheter ablation as a viable treatment option for atrial fibrillation in these patients." Of the 69 patients, 34 had paroxysmal AF and 25 had complex CHD. The team defined complete success as freedom from recurrent AF for one year off antiarrhythmic medications, and partial success as freedom from AF recurrences for one year on previously ineffective anti-arrhythmic medications. At one year, researchers concluded that 53 percent of the patients had complete success with an additional 13 percent experiencing partial success. 92 percent of patients underwent a PVI approach, while seven percent had a non-PVI ablation alone. "We also found that 12 patients needed a repeat ablation within the first year, but most notably, there were no major procedural complications identified and only five minor complications, which is on par with rates in non-CHD patients," said Liang. "While PVI should remain the cornerstone of ablation, an individualized approach utilizing pre-procedural imaging to help to define the anatomy is necessary to improve outcomes in patients with CHD." Researchers conclude that AF ablation in this complex population was safe and effective, with similar outcomes to those seen in non-CHD patients, despite anatomical differences. However, they noted that more research is needed to further define the challenges and optimal ablation strategies in CHD patients. Penn Medicine is one of the world's leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System, which together form a $6.7 billion enterprise. The Perelman School of Medicine has been ranked among the top five medical schools in the United States for the past 20 years, according to U.S. News & World Report's survey of research-oriented medical schools. The School is consistently among the nation's top recipients of funding from the National Institutes of Health, with $392 million awarded in the 2016 fiscal year. The University of Pennsylvania Health System's patient care facilities include: The Hospital of the University of Pennsylvania and Penn Presbyterian Medical Center -- which are recognized as one of the nation's top "Honor Roll" hospitals by U.S. News & World Report -- Chester County Hospital; Lancaster General Health; Penn Wissahickon Hospice; and Pennsylvania Hospital -- the nation's first hospital, founded in 1751. Additional affiliated inpatient care facilities and services throughout the Philadelphia region include Good Shepherd Penn Partners, a partnership between Good Shepherd Rehabilitation Network and Penn Medicine. Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2016, Penn Medicine provided $393 million to benefit our community.


Event Hosted by Mike & Mickie Krzyzewski has Raised More than $80 Million for Cancer Research to Date Napa Valley, CA – [Tuesday, May 9, 2017] – The V Foundation for Cancer Research, a top-rated cancer research charity, and the V Foundation Wine Celebration will celebrate their 19th annual event August 3-6, 2017, in Napa Valley.  Hosted once again by Duke University’s Head Men’s Basketball Coach Mike Krzyzewski and his wife Mickie, this year’s “Fund-A-Need” will support a $6 million challenge grant that will fund emerging, high-impact research of cancers that derive from BRCA or BRCA-like mutations.  The challenge was first announced in December during the V Foundation’s launch of its $200 million capital campaign, Not a Moment to Lose. The campaign is designed to build on the momentum behind extraordinary research findings that will achieve victory over cancer. Since 1999, the V Foundation Wine Celebration, benefitting the V Foundation for Cancer Research, has raised over $80 million for cancer research and related programs. This three-day signature series of events in stunning Napa Valley demonstrates that commitment, passion and giving become the catalyst for positive change. Experience the best culinary adventures, the most sought after wines, exciting performances, thought-provoking panels and the chance to meet amazing people from all over the country who are joining the fight along with you – the fight to find cures for cancer. “The Wine Celebration is a combination of remarkable wine, food and people, coming together to celebrate our lives and to raise much-needed funds for cancer research,” said Susan Braun, CEO of the V Foundation. “This year, we’re targeting research that helps us better understand why some people have a higher risk of cancer and how we can change the course of inherited risks.” The Wine Celebration’s “Fund-A-Need” will advance the research of inherited mutations in BRCA1 and BRCA2 genes that produce tumor suppressor proteins.  The BRCA Foundation, founded by V Foundation Board of Directors member Evan Goldberg, and the Gray Foundation have each pledged $1.5 million towards the challenge grant.  With a successful match by the V Foundation to the challenge, at least $6 million will be awarded to cutting-edge research exploring why women and men with a mutated copy of either the BRCA1 or BRCA2 gene are at a significantly increased risk of developing cancer.  Though initial studies focused on breast and ovarian cancer, new research shows the mutation also increases the risks of pancreatic cancer, male breast cancer and prostate cancer.  A subset of the V Foundation’s Scientific Advisory Committee and other experts, including Dr. Susan Domchek from the Basser Center for BRCA at the Abramson Cancer Center and Dr. Alan Ashworth from the University of California San Francisco, will award the BRCA Research Collaborative Grants to the best projects at institutions nationwide.  Members of the Scientific Advisory Committee, which is comprised of some of the nation’s leading physicians and research scientists, will discuss current advances, alternative treatments and discoveries into clinical applications during the Wine Celebration’s “Answer for Cancer Research Symposium” on August 5. “It is a dream come true for me to see a collaboration between these three organizations,” said Goldberg. “With a stellar grant committee made up of scientists associated with each organization and a donation match that can catalyze giving to the cause, this whole effort is destined to be far greater than the sum of its parts.” In raising $200 million by 2020 with the Not a Moment to Lose fundraising campaign, the V Foundation will strategically focus on research aimed to transform the treatment, detection and prevention of cancer.  In addition to the BRCA Research Collaborative Grants, areas of scientific research to be funded through Not a Moment to Lose include the study of prevention signals, clinical trials, immunotherapy pathways, big data collaborations and convergence projects, as well as pediatric cancer and translational research. For more information about the V Wine Celebration, please visit www.winecelebration.org.  For more about the V Foundation and its mission to achieve victory over cancer, please visit www.jimmyv.org. About the V Foundation for Cancer Research The V Foundation for Cancer Research is dedicated to declaring victory over cancer.  It was founded in 1993 by ESPN and the late Jim Valvano, legendary North Carolina State Basketball coach and ESPN commentator.  Since 1993, the Foundation has funded more than $170 million in cancer research grants nationwide.  It awards 100 percent of all direct cash donations to cancer research and related programs.  Due to generous donors, the Foundation has an endowment that covers administrative expenses.  Not a Moment to Lose, its boldest fundraising campaign to date, aims to raise $200 million for cancer research by 2020 to help transform the prevention, detection and treatment of cancer.  The Foundation awards peer-reviewed grants through a competitive awards process vetted by a world-renowned Scientific Advisory Committee.  For more information on the V Foundation, please visit www.jimmyv.org. The V Foundation Wine Celebration is a world-class wine event and auction benefiting the V Foundation for Cancer Research. Set in Napa Valley, the heart of California Wine Country, this annual special event brings together 500 prominent members of the sports broadcasting, entertainment, media, lifestyle, technology, investment, medical and winemaking worlds to raise money to fund vital research in the fight against all types of cancer. The V Wine Celebration has helped fund 600 research programs at medical and research facilities across the country. Dedicated to giving back to the generous Napa Valley and surrounding communities that have so enthusiastically embraced it, the Foundation has included many Bay Area institutions among its grantees, including St. Helena Hospital, Queen of the Valley Medical Center in Napa, Stanford University and UC San Francisco. Founded by Julie Allegro, the V Foundation Wine Celebration has grown to be to one of the top-rated charitable auctions in the country. For more information on the V Foundation Wine Celebration, please visit winecelebration.org.


NEW YORK, May 09, 2017 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, today announced the addition to its advisory board of Dr. Donald Abrams, chief of the Hematology-Oncology Division at San Francisco General Hospital and a Professor of Clinical Medicine at the University of California San Francisco. A photo accompanying this announcement is available at: http://www.globenewswire.com/NewsRoom/AttachmentNg/b1dcfc25-e7da-4d33-a468-99714b731345 “We are very pleased and honored to have Dr. Abrams join our Advisory Board,” said George E. Anastassov, MD, DDS, MBA and Chief Executive Officer of AXIM® Biotech. “In addition to being an oncology specialist who was one of the original clinicians to recognize and define many early AIDS-related conditions, Dr. Abrams has authoritative expertise in medicinal cannabis research and clinical trials. Working with AXIM management and other members of our advisory board, Dr. Abrams will further enhance the intellectual rigor of our research and help better address patient needs with cannabinoid based pharmaceutical solutions.” “I am excited to be joining the board as I am impressed with AXIM’s innovative technology aiming to make cannabis-based medicines available to a larger population of patients through its novel delivery systems,” said Dr. Abrams. Dr. Abrams has long been involved in clinical trials of complementary and alternative medicine interventions for HIV/AIDS and cancer, including evaluations of medicinal marijuana. In 1997, Dr. Abrams received funding from the National Institute on Drug Abuse to conduct clinical trials of the short-term safety of cannabinoids in HIV infection. Subsequently, he was granted funds by the University of California Center for Medicinal Cannabis Research to continue studies of the effectiveness of cannabis in a number of clinical conditions. Dr. Abrams completed a placebo-controlled study of smoked cannabis in patients with painful HIV-related peripheral neuropathy as well as a study evaluating vaporization as a smokeless delivery system for medicinal purposes. Dr. Abram’s NIDA-funded trial investigated the possible pharmacokinetic interaction between vaporized cannabis and opioid analgesics in patients with chronic pain. Dr. Abrams is conducting an NIH-funded trial investigating vaporized cannabis in patients with Sickle Cell disease. He co-authored the chapter on “Cannabinoids and Cancer” in the Oxford University Press Integrative Oncology text that he co-edited with Andrew Weil. He co-edits the NCI PDQ CAM Cannabinoids and Cancer website. Dr. Abrams was a member of the National Academies of Sciences, Engineering and Medicine’s committee that published The Health Effects of Cannabis and Cannabinoids: Current State of Evidence and Recommendations for Research in January 2017. About AXIM® AXIM® Biotechnologies, Inc. (OTC:AXIM) focuses on the research, development and production of cannabis-based pharmaceutical, nutraceutical and cosmetic products. Our flagship products include CanChew®, a CBD-based controlled release chewing gum, and MedChew Rx, a combination CBD/THC gum that is undergoing clinical trials for the treatment of pain and spasticity associated with multiple sclerosis. We prioritize the well-being of our customers while embracing a solid fiscal strategy. For more information, please visit www.AXIMBiotech.com. FORWARD-LOOKING DISCLAIMER This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Axim Biotechnologies, Inc. to be materially different from the statements made herein. LEGAL DISCLOSURE AXIM® Biotechnologies does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA).


NEW YORK, May 09, 2017 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, today announced the addition to its advisory board of Dr. Donald Abrams, chief of the Hematology-Oncology Division at San Francisco General Hospital and a Professor of Clinical Medicine at the University of California San Francisco. A photo accompanying this announcement is available at: http://www.globenewswire.com/NewsRoom/AttachmentNg/b1dcfc25-e7da-4d33-a468-99714b731345 “We are very pleased and honored to have Dr. Abrams join our Advisory Board,” said George E. Anastassov, MD, DDS, MBA and Chief Executive Officer of AXIM® Biotech. “In addition to being an oncology specialist who was one of the original clinicians to recognize and define many early AIDS-related conditions, Dr. Abrams has authoritative expertise in medicinal cannabis research and clinical trials. Working with AXIM management and other members of our advisory board, Dr. Abrams will further enhance the intellectual rigor of our research and help better address patient needs with cannabinoid based pharmaceutical solutions.” “I am excited to be joining the board as I am impressed with AXIM’s innovative technology aiming to make cannabis-based medicines available to a larger population of patients through its novel delivery systems,” said Dr. Abrams. Dr. Abrams has long been involved in clinical trials of complementary and alternative medicine interventions for HIV/AIDS and cancer, including evaluations of medicinal marijuana. In 1997, Dr. Abrams received funding from the National Institute on Drug Abuse to conduct clinical trials of the short-term safety of cannabinoids in HIV infection. Subsequently, he was granted funds by the University of California Center for Medicinal Cannabis Research to continue studies of the effectiveness of cannabis in a number of clinical conditions. Dr. Abrams completed a placebo-controlled study of smoked cannabis in patients with painful HIV-related peripheral neuropathy as well as a study evaluating vaporization as a smokeless delivery system for medicinal purposes. Dr. Abram’s NIDA-funded trial investigated the possible pharmacokinetic interaction between vaporized cannabis and opioid analgesics in patients with chronic pain. Dr. Abrams is conducting an NIH-funded trial investigating vaporized cannabis in patients with Sickle Cell disease. He co-authored the chapter on “Cannabinoids and Cancer” in the Oxford University Press Integrative Oncology text that he co-edited with Andrew Weil. He co-edits the NCI PDQ CAM Cannabinoids and Cancer website. Dr. Abrams was a member of the National Academies of Sciences, Engineering and Medicine’s committee that published The Health Effects of Cannabis and Cannabinoids: Current State of Evidence and Recommendations for Research in January 2017. About AXIM® AXIM® Biotechnologies, Inc. (OTC:AXIM) focuses on the research, development and production of cannabis-based pharmaceutical, nutraceutical and cosmetic products. Our flagship products include CanChew®, a CBD-based controlled release chewing gum, and MedChew Rx, a combination CBD/THC gum that is undergoing clinical trials for the treatment of pain and spasticity associated with multiple sclerosis. We prioritize the well-being of our customers while embracing a solid fiscal strategy. For more information, please visit www.AXIMBiotech.com. FORWARD-LOOKING DISCLAIMER This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Axim Biotechnologies, Inc. to be materially different from the statements made herein. LEGAL DISCLOSURE AXIM® Biotechnologies does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA).


NEW YORK, May 09, 2017 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, today announced the addition to its advisory board of Dr. Donald Abrams, chief of the Hematology-Oncology Division at San Francisco General Hospital and a Professor of Clinical Medicine at the University of California San Francisco. A photo accompanying this announcement is available at: http://www.globenewswire.com/NewsRoom/AttachmentNg/b1dcfc25-e7da-4d33-a468-99714b731345 “We are very pleased and honored to have Dr. Abrams join our Advisory Board,” said George E. Anastassov, MD, DDS, MBA and Chief Executive Officer of AXIM® Biotech. “In addition to being an oncology specialist who was one of the original clinicians to recognize and define many early AIDS-related conditions, Dr. Abrams has authoritative expertise in medicinal cannabis research and clinical trials. Working with AXIM management and other members of our advisory board, Dr. Abrams will further enhance the intellectual rigor of our research and help better address patient needs with cannabinoid based pharmaceutical solutions.” “I am excited to be joining the board as I am impressed with AXIM’s innovative technology aiming to make cannabis-based medicines available to a larger population of patients through its novel delivery systems,” said Dr. Abrams. Dr. Abrams has long been involved in clinical trials of complementary and alternative medicine interventions for HIV/AIDS and cancer, including evaluations of medicinal marijuana. In 1997, Dr. Abrams received funding from the National Institute on Drug Abuse to conduct clinical trials of the short-term safety of cannabinoids in HIV infection. Subsequently, he was granted funds by the University of California Center for Medicinal Cannabis Research to continue studies of the effectiveness of cannabis in a number of clinical conditions. Dr. Abrams completed a placebo-controlled study of smoked cannabis in patients with painful HIV-related peripheral neuropathy as well as a study evaluating vaporization as a smokeless delivery system for medicinal purposes. Dr. Abram’s NIDA-funded trial investigated the possible pharmacokinetic interaction between vaporized cannabis and opioid analgesics in patients with chronic pain. Dr. Abrams is conducting an NIH-funded trial investigating vaporized cannabis in patients with Sickle Cell disease. He co-authored the chapter on “Cannabinoids and Cancer” in the Oxford University Press Integrative Oncology text that he co-edited with Andrew Weil. He co-edits the NCI PDQ CAM Cannabinoids and Cancer website. Dr. Abrams was a member of the National Academies of Sciences, Engineering and Medicine’s committee that published The Health Effects of Cannabis and Cannabinoids: Current State of Evidence and Recommendations for Research in January 2017. About AXIM® AXIM® Biotechnologies, Inc. (OTC:AXIM) focuses on the research, development and production of cannabis-based pharmaceutical, nutraceutical and cosmetic products. Our flagship products include CanChew®, a CBD-based controlled release chewing gum, and MedChew Rx, a combination CBD/THC gum that is undergoing clinical trials for the treatment of pain and spasticity associated with multiple sclerosis. We prioritize the well-being of our customers while embracing a solid fiscal strategy. For more information, please visit www.AXIMBiotech.com. FORWARD-LOOKING DISCLAIMER This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Axim Biotechnologies, Inc. to be materially different from the statements made herein. LEGAL DISCLOSURE AXIM® Biotechnologies does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA).


NEW YORK, May 09, 2017 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, today announced the addition to its advisory board of Dr. Donald Abrams, chief of the Hematology-Oncology Division at San Francisco General Hospital and a Professor of Clinical Medicine at the University of California San Francisco. A photo accompanying this announcement is available at: http://www.globenewswire.com/NewsRoom/AttachmentNg/b1dcfc25-e7da-4d33-a468-99714b731345 “We are very pleased and honored to have Dr. Abrams join our Advisory Board,” said George E. Anastassov, MD, DDS, MBA and Chief Executive Officer of AXIM® Biotech. “In addition to being an oncology specialist who was one of the original clinicians to recognize and define many early AIDS-related conditions, Dr. Abrams has authoritative expertise in medicinal cannabis research and clinical trials. Working with AXIM management and other members of our advisory board, Dr. Abrams will further enhance the intellectual rigor of our research and help better address patient needs with cannabinoid based pharmaceutical solutions.” “I am excited to be joining the board as I am impressed with AXIM’s innovative technology aiming to make cannabis-based medicines available to a larger population of patients through its novel delivery systems,” said Dr. Abrams. Dr. Abrams has long been involved in clinical trials of complementary and alternative medicine interventions for HIV/AIDS and cancer, including evaluations of medicinal marijuana. In 1997, Dr. Abrams received funding from the National Institute on Drug Abuse to conduct clinical trials of the short-term safety of cannabinoids in HIV infection. Subsequently, he was granted funds by the University of California Center for Medicinal Cannabis Research to continue studies of the effectiveness of cannabis in a number of clinical conditions. Dr. Abrams completed a placebo-controlled study of smoked cannabis in patients with painful HIV-related peripheral neuropathy as well as a study evaluating vaporization as a smokeless delivery system for medicinal purposes. Dr. Abram’s NIDA-funded trial investigated the possible pharmacokinetic interaction between vaporized cannabis and opioid analgesics in patients with chronic pain. Dr. Abrams is conducting an NIH-funded trial investigating vaporized cannabis in patients with Sickle Cell disease. He co-authored the chapter on “Cannabinoids and Cancer” in the Oxford University Press Integrative Oncology text that he co-edited with Andrew Weil. He co-edits the NCI PDQ CAM Cannabinoids and Cancer website. Dr. Abrams was a member of the National Academies of Sciences, Engineering and Medicine’s committee that published The Health Effects of Cannabis and Cannabinoids: Current State of Evidence and Recommendations for Research in January 2017. About AXIM® AXIM® Biotechnologies, Inc. (OTC:AXIM) focuses on the research, development and production of cannabis-based pharmaceutical, nutraceutical and cosmetic products. Our flagship products include CanChew®, a CBD-based controlled release chewing gum, and MedChew Rx, a combination CBD/THC gum that is undergoing clinical trials for the treatment of pain and spasticity associated with multiple sclerosis. We prioritize the well-being of our customers while embracing a solid fiscal strategy. For more information, please visit www.AXIMBiotech.com. FORWARD-LOOKING DISCLAIMER This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Axim Biotechnologies, Inc. to be materially different from the statements made herein. LEGAL DISCLOSURE AXIM® Biotechnologies does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA).

Loading University of California San Francisco collaborators
Loading University of California San Francisco collaborators